No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators

Price, DavidHenley, WilliamCarter, VictoriaSkinner, DeborahVella, RebeccaPapi, A.Fabbri, L MKertsjens, HRoche, NicolasSingh, DaveVogelmeier, CSen, ECancado, JNudo, ElenaBarile, SaraGeorges, George2024-04-252024-04-252022-03-16Price, D, Henley, W, Carter, V, Skinner, D, Vella, R, Papi, A, Fabbri, L M, Kertsjens, H, Roche, N, Singh, D, Vogelmeier, C, Sen, E, Cancado, J, Nudo, E, Barile, S & Georges, G 2022, 'No difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilators', Respirology, vol. 27, no. S1, TO 016, pp. 28-29. https://doi.org/10.1111/resp.142161323-7799https://hdl.handle.net/2164/233482106529engR MedicineRNo difference in pneumonia risk in COPD patients initiating fixed dose combination (FDC) inhaler comprising extrafine beclometasone dipropionate versus long-acting bronchodilatorsJournal item10.1111/resp.1421627